[Comparative effectiveness of medication therapies in the rheumatoid arthritis patients]

Hyun MK, Choi M, Choi S, Tchoe HJ, Lee SY, Son KM, Jung YO, Kim HA
Record ID 32014001105
Authors' recommendations: The objective of this study was to assess the current status and identify the most effective treatment sequence of therapies for patients with rheumatoid arthritis, by utilizing a new systematic review. A mixed-treatment comparison was carried out with a systematic literature review using secondary information sources, including the analysis of claims application data submitted to the National Health Insurance. However, there were limitations to the study due to a lack of existing research data. The degree of joint damage was difficult to assess in a quantitative manner using the joint count method or the standardized Sharp score method because it required a lot of time and effort to measure 28-68 joints and to reflect those results in the treatment scores. In addition, most of the drug comparative effectiveness research currently being done focuses mainly on second-line agents including biological agents. Therefore, the publication of a prospective clinical research in the future to compare the effectiveness of RA drugs (for example, comparing DMARDs and biological agents) will enable the development of improved guidelines for the prescription of cost-effective drug regimens for the treatment of RA.
Project Status: Completed
Year Published: 2014
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: South Korea
MeSH Terms
  • Antirheumatic Agents
Organisation Name: National Evidence-based healthcare Collaborating Agency
Contact Address: National Evidence-based Healthcare Collaborating Agency (NECA), 3~5F Health and Welfare Social Administration B/D, 400 Neungdong-ro, Gwangjin-gu, Seoul, Korea.
Contact Name: int@neca.re.kr
Contact Email: int@neca.re.kr
Copyright: National Evidence-based Healthcare Collaborating Agency (NECA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.